Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
⏸️ Investing
My 3 market-beating share picks for 2017
⏸️ Investing
Market Movers: Why these 5 shares are ROCKETING higher today
⏸️ Investing
Why these 4 ASX shares have started the week with BIG declines
⏸️ Investing
ASX 200 to slip: 6 shares you need to watch today
⏸️ Investing
ASX 200 slips: 11 shares you should have been watching
⏸️ Investing
Why these 4 ASX shares have been SMASHED today
⏸️ Investing
CRASH! Why Mayne Pharma Group Ltd's share price plunged 22% today
⏸️ Investing
10 growth shares I'm tipping to shine in 2017
⏸️ Investing
Why these 4 ASX shares are sinking like stones today
⏸️ Investing
Why Orion Health Group Ltd is one of 4 shares ending the week on fire
⏸️ Investing
Why Donald Trump is rattling Mayne Pharma Group Ltd investors
⏸️ Investing
4 ASX bargains at the top of my Christmas shopping list
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
